QUICK GUIDE

Rare Disease Quick Guide

We partner **with** your people **for your** patients

Aligned for Agility

Your goals are our goals- to focus on the patient. Caidya takes a **patient-centric approach** as we deliver personalized services designed around the specific needs of **patients**, **caregivers**, and sites. Our deep understanding of the intricacies involved in rare disease trials allows us to partner with you in creating bespoke strategies that not only streamline the development process but also boost the chances of achieving ground-breaking outcomes.

Execution – Partnerships through People

Researching rare diseases is a meticulous process that requires careful planning and execution. We focus on developing robust protocols with specific criteria to ensure the right **patients** are included and the right sites are selected. Our goal is to overcome the unique hurdles your clinical trial may face.

Expertise that Matters

- **23,000 patients**
- across 180+ sites worldwide.

Our experience in rare disease drug development spans many rare types of cancers, including multiple myeloma, hepatocellular carcinoma, leukemia, lymphoma, and skin cancer.

Beyond oncology, we have also supported studies in immunological rare diseases, rare genetic disorders, rare blood disorders, and rare neurological diseases.

Our People

Jonathan Kornstein, VP Rare Disease and Pediatrics

Jonathan has over 29 years of experience in the Pharmaceutical and CRO industry. He has demonstrated a depth of project management and clinical operations experience in a multitude of therapeutic areas. Jonathan provides strategic consultation and direction to clinical management, commercial development, and business development teams facilitating overall success in clinical trials. Jonathan takes a **patient centered approach** when implementing clinical trials and has a significant amount of experience overseeing rare indications in clinical trials.

Jonathan holds a bachelor's degree in biology from Hamilton College in Clinton, New York and is homebased in Chapel Hill, North Carolina.

Adam Marsh, Senior Director, Clinical Development

Adam has over 14 years of clinical trial experience with 10+ years of leading clinical trial teams. His extensive rare disease study experience is critical to Caidya's white-glove approach.

Adam holds a PhD from University of Nottingham and is homebased in Tiverton, England

"We're driven to advance rare disease studies while reducing patient and caregiver burden. Working alongside drug development sponsors, we are working to accelerate these complex studies and help address urgent unmet medical needs for people living with a rare disease."

– Jonathan Kornstein
VP Rare Disease & Pediatrics

caidya®

Adapting at The Speed of Science

Clinipace, Inc. is owned, operated, managed, and controlled by dMedClinical Co. Ltd., a privately held company, whose investors include entities located in the People's Republic of China (PRC), and which may be subject to PRC laws and regulations that differ from those of the United States.